Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Sep 09, 2022 2:02pm
108 Views
Post# 34952727

RE:RE:RE:Down again

RE:RE:RE:Down again

I remember one time being told quietly by my CFO that I just couldn't sell my options at a certain point in time. No more questions. I was only a lowly scientist, maybe the egos of execs won't take that sort of instruction but they should know better the reasons for not selling than I did at that time.

It's a big assumption at present that there will be a large unloading of options. In general terms the problem with THTX is not that they are all making terrible decisions against our interests but that what they've been chasing to increase value has hit brick walls (Trogarzo sales and the NASH program). They are mostly boringly vanilla, conservative, a mass dump of options is too exciting for them. (Watch it happen now that I've said this)


Wino115 wrote:

You could, but it could be taken as a negative too ... I.e., why didnt inside officers want to gain more exposure and instead pushed the date off? Also, adding time to any option is a value transfer to the holder worth something, using the Black Scholes formula. The simple answer is these managers work for the company and should want to own shares to incentivize them to grow its value. They knew this coming in, accepting employment, so if they just want a cash+bonus compensation scenario, go work for some big ugly company or the Govt.  No upside risk exposure but safe annual cash comp, much lower likely.

 

Lee430 wrote: Question, to prevent the potential ugly sell off of expiring stock grant's is it possible for the BOD to simply extend the expiration date or re issue them with a later date?

 

 



<< Previous
Bullboard Posts
Next >>